Transient Ischemic Attack Clinical Trial
Official title:
Back to Normal - Multiple Non-pharmacological Interventions to Accelerate the Return to the Pre-event Level of Functioning After a Transient Ischemic Attack and Minor Stroke - a Pilot Randomized Controlled Trial
The occurrence of a transient ischemic attack (TIA) or a minor stroke is frequently assumed as a temporary and non-disabling event. Nevertheless, patients can experience subtle but meaningful impairments, including a decreased performance in activities of daily living (ADLs), a high prevalence of depression, cognitive decline, physical deficits, hearing degeneration, with implications in returning to work, social relations and activities. Additionally, it has been described a higher risk of stroke among these patients, which highlights the importance of promoting secondary prevention, soon after these acute episodes. Therefore, this pilot randomized controlled trial (RCT) aims to evaluate the feasibility and the effectiveness of a three-month multidomain intervention program, composed of five non-pharmacological components which may contribute to accelerate the return to the pre-event level of functioning in patients with TIA and minor stroke. The results may guide future clinical practices and health policies aiming to reduce the overall burden of stroke.
Status | Recruiting |
Enrollment | 70 |
Est. completion date | December 2022 |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Aged 18-85 years old; - Clinical diagnosis of transient ischemic stroke or minor stroke as defined by the National Institute of Health Stroke Scale score =3; - Onset of symptoms within the last seven days; - First-time stroke or TIA; - Four or more years of education; - Discharged home without the need for inpatient rehabilitation; - Modified Rankin Scale 0 to 2, inclusive. Exclusion Criteria: - Unable to attend the face-to-face intervention sessions; - Previous diagnosis of Dementia or severe disability; - Contraindication for physical exercise; - Severe loss of hearing, vision, or communication skills; - Frailty, reduced life expectancy due to severe disease or need for regular treatments that compete with availability for intervention. |
Country | Name | City | State |
---|---|---|---|
Portugal | Instituto de Saúde Pública da Universidade do Porto | Porto |
Lead Sponsor | Collaborator |
---|---|
Instituto de Saude Publica da Universidade do Porto |
Portugal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to recovery in each instrumental activity of daily living | Time to recovery in each instrumental activity of daily living measured by an adapted version of the Frenchay Activities Index. | 3 months | |
Primary | Recruitment timeframe | Proportion of participants recruited within the seven days post-onset of symptoms will be calculated as the number of participants recruited within the time frame divided by the total number of participants. | 3 months | |
Primary | Adherence to each component of the intervention | Proportion of adherence to each component of the intervention and to different intervention modalities (remote/in person), calculated as the number of sessions attended divided by the total number of sessions implemented. For remote cognitive training the outcome will be the absolute number of sessions. | 3 months | |
Primary | Dropout | Proportion of participants who dropped out of the study, calculated as the number of participants who dropped out after attending at least one session divided by the total number of participants who attended at least one session. | 3 months | |
Secondary | Time of follow-up | Number of days between the first and the last session attended by the participant. | 3 months | |
Secondary | Complete assessment of participants | For each study outcome, proportion of participants with complete information, calculated at baseline and follow-up, as the number of participants with complete information divided by the total number of participants evaluated. | 3 months | |
Secondary | Implemented sessions | Proportion of sessions implemented, calculated as the number of sessions that the research team was able to implement divided by the total number of sessions planned. | 3 months | |
Secondary | Cognitive performance | Variation of participant's cognitive performance assessed using the Montreal Cognitive Assessment, between the baseline and the follow-up assessments. This scale varies from 0 (worst cognitive performance) to 30 points (best cognitive performance). | 3 months | |
Secondary | Memory complaints | Variation of the self-reported memory complaints, assessed using the Subjective Memory Complaints Scale, between the baseline and follow-up assessments. This scale varies from 0 (best score) to 21 points (worst score). Scores over three points indicate the presence of self-reported memory complaints. | 3 months | |
Secondary | Adherence to the Mediterranean diet | Variation of participant's self-reported adherence to the Mediterranean diet, assessed using the Mediterranean food pattern (MEDAS) scale, between the baseline and the follow-up assessments. This scale varies from 0 (lowest adherence to the Mediterranean diet) to 14 points (highest adherence to the Mediterranean diet). A score over 10 points indicates good adherence to the Mediterranean diet. | 3 months | |
Secondary | Anxiety and depression | Variation of the anxiety and depression scores, assessed using the Hospital Anxiety and Depression Scale (HADS), between the baseline and the follow-up assessments. This scale varies from 0 (best score) to 21 points (worst score). | 3 months | |
Secondary | Reported quality of life | Variation of participant's quality of life, assessed using the EuroQol Group scale - 5 dimensions (EQ-5D) scale, between the baseline and the follow-up assessments. This scale is subdivided in two subscales: a) five multiple choice questions, with five response possibilities, which produce a score that varies from 5 (best score) to 25 points (worst score); b) visual analogic scale, that varies from 0 (worst score) to 100 (best score). | 3 months | |
Secondary | Handgrip strength | Variation of participant's handgrip strength, assessed using a dynamometer, between the baseline and the follow-up assessments. | 3 months | |
Secondary | Agility 1 | Variation of participant's agility and balance, assessed using the Timed Up and Go Test scale, between the baseline and the follow-up assessments. This is measured in time units (seconds) and varies from 0 (best score) to infinite (worst score). | 3 months | |
Secondary | Agility 2 | Variation of participant's agility and balance, assessed using the Unipedal Stance Test, between the baseline and the follow-up assessments. This is measured in time units (seconds) and varies from 0 (best score) to infinite (worst score). | 3 months | |
Secondary | Upper body strength | Variation of participant's upper body strength assessed using the 30-second arm curl test, from the Senior Fitness Test. | 3 months | |
Secondary | Lower body strength | Variation of participant's lower body strength assessed using the 30-second chair stand test, from the Senior Fitness Test. | 3 months | |
Secondary | Upper body flexibility | Variation of participant's upper body flexibility assessed using the back-scratch test, from the Senior Fitness Test. | 3 months | |
Secondary | Lower body flexibility | Variation of participant's lower body flexibility assessed using the chair sit-and-reach test, from the Senior Fitness Test. | 3 months | |
Secondary | Agility 3 | Variation of participant's agility and dynamic balance assessed using the 8-foot distance test (2,44 meters), from the Senior Fitness Test. | 3 months | |
Secondary | Aerobic endurance | Variation of participant's aerobic endurance assessed using the 2-minute step test, from the Senior Fitness Test. | 3 months | |
Secondary | Lower limb function | Variation of participant's lower limb function, assessed using the Short Physical Performance Battery (SPPB), which tests 3 dimensions: standing balance, walking speed, and chair stands. Each component is scored between 0-4, total score from 0 (poor performance) to 12 (best performance). | 3 months | |
Secondary | Functional capacity to perform basic activities of daily living | Variation of participant's independence on performing basic activities of daily living, using the Barthel Index, which ranges from 0 to 20 and higher scores represent increased functionality and independence. | 3 months | |
Secondary | Disability | Variation of participant's disability assessed via modified Rankin Scale, with scores ranging from 0 (perfect health) to 6 (dead). | 3 months | |
Secondary | 24-hour urinary sodium excretion | Variation of participant's urinary sodium excretion, between the baseline and the follow-up assessments. This parameter will be measured through a laboratory analysis of participants' 24-hour urinary samples and will be analyzed as a proxy of dietary salt intake. | 3 months | |
Secondary | 24-hour urinary potassium excretion | Variation of participant's urinary potassium excretion, between the baseline and the follow-up assessments. This parameter will be measured through a laboratory analysis of participants' 24-hour urinary samples and will be analyzed as a proxy of dietary potassium intake. | 3 months | |
Secondary | Levels of glycated hemoglobin | Variation of participant's levels of glycated hemoglobin, between the baseline and the follow-up assessments. This parameter will be measured through a laboratory analysis of participants' blood sample and will be used to analyze glycemic control. | 3 months | |
Secondary | Body mass index | Variation of participant's body mass index between the baseline and the follow-up assessments. | 3 months | |
Secondary | Blood pressure | Variation of participant's systolic and diastolic blood pressure between the baseline and the follow-up assessments. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00859885 -
International PFO Consortium
|
N/A | |
Not yet recruiting |
NCT03605355 -
Feasibility Study on the Medical and Economic Consequences of Outpatient Management of TIAs and Minor Strokes
|
||
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Completed |
NCT02905383 -
The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital
|
N/A | |
Completed |
NCT04078737 -
Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II
|
Phase 3 | |
Completed |
NCT02141932 -
Pocket-size Cardiovascular Ultrasound in Stroke
|
N/A | |
Recruiting |
NCT01954329 -
Markers in the Diagnosis of TIA
|
N/A | |
Completed |
NCT02011256 -
Early Detection Of Atrial Fibrillation In Patients With Transient Ischemic Attack
|
N/A | |
Completed |
NCT01918891 -
Center for Stroke Disparities Solution - Community Transitions Intervention
|
N/A | |
Recruiting |
NCT01526824 -
Lovaza's Effect on Clopidogrel in a Neuro Population
|
Phase 0 | |
Completed |
NCT01020851 -
The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attack (TIA) or Stroke Trial
|
N/A | |
Completed |
NCT00597974 -
Neurological Outcome With Carotid Artery Stenting
|
N/A | |
Completed |
NCT00211731 -
Preventing Recurrent Stroke in Minority Populations
|
N/A | |
Active, not recruiting |
NCT03635749 -
Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis
|
Phase 3 | |
Completed |
NCT03153020 -
Determinants of Adherence to Post-stroke/Transient Ischemic Attack Secondary Prevention Treatment: Cohort Study in the Rhône
|
||
Recruiting |
NCT04075500 -
Optimal Detection of Atrial Fibrillation in TIA
|
N/A | |
Recruiting |
NCT06091319 -
Florbetaben for Imaging of Vascular Amyloid
|
||
Completed |
NCT04604015 -
RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt
|
N/A | |
Completed |
NCT00885456 -
Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke or Transient Ischemic Attack: A Multi-site RCT
|
Phase 2 | |
Completed |
NCT05620966 -
EEG to Diagnose TIA and Stroke
|